• OPEN AN ACCOUNT
Indian Indices
Nifty
22,302.50 0.00
(0.00%)
Sensex
73,466.39 -45.46
( -0.06%)
Bank Nifty
48,021.10 -264.25
( -0.55%)
Nifty IT
33,335.15 -137.85
( -0.41%)
Global Indices
Nasdaq
16,302.76 -29.80
(-0.18%)
Dow Jones
39,056.39 172.13
(0.44%)
Hang Seng
18,313.86 -165.51
(-0.90%)
Nikkei 225
38,202.37 -632.73
(-1.63%)
Forex
USD-INR
83.47 0.09
(0.11%)
EUR-INR
89.90 0.16
(0.18%)
GBP-INR
104.87 0.26
(0.25%)
JPY-INR
0.54 0.00
(-0.42%)

EQUITY - MARKET SCREENER

Lupin Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500257
INE326A01037
452.0701112
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LUPIN
31.66
73640.1
EPS(TTM)
Face Value()
Div & Yield %
51.04
2
0.5
 

lupin ltd
Lupin Launches Mirabegron tablets
Apr 22,2024
Mirabegron extended-release tablets, 25 mg is a generic equivalent of Myrbetriq extended-release tablets, 25 mg of Astellas Pharma Global Development, Inc. It is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.

As per IQVIA MAT February 2024, Mirabegron extended-release tablets USP 25mg and 50mg had annual sales of $2.42billion in the United States.

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The drug major reported consolidated net profit of Rs 613.12 crore in Q3 FY24, steeply higher from Rs 153.47 crore posted in Q3 FY23. Revenue from operations jumped 19.67% year on year to Rs 5,079.9 crore during the quarter.

The scrip fell 2.92% to end at Rs 1,547.05 on Friday, 19 April 2024.